12 Numbers in Pfizer's Q2 Update More Important Than Its Revenue Decline
Pfizer (NYSE: PFE) announced its second-quarter results before the market opened on Tuesday. And investors yawned -- at least for the most part.
Many of the headlines about the big drugmaker's quarterly performance centered on Pfizer's year-over-year revenue decline. The company reported second-quarter revenue of $12.9 billion, down 2% from the prior-year period and below the consensus analysts' estimate. Most of this drop stemmed from Pfizer's sale of its Hospira Infusion Systems (HIS) business earlier this year.
The revenue figure actually isn't the most important thing for investors to pay attention to in Pfizer's results, though. Here are 12 numbers in the company's second-quarter update that matter more now and for the future.
Source: Fool.com
Pfizer Inc. Aktie
Die Pfizer Inc. Aktie steht gut da: Deutlich mehr Buy- als Sell-Einschätzungen in der Community.
Das Kursziel von 41 € für Pfizer Inc. impliziert eine deutliche Steigerung um über 50% gegenüber 25.77 €.
